Company intelligence / Profile preview

ReCode Therapeutics

Menlo Park, California, United Statesrecodetx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ReCode’s lead programs—RCT1100 for primary ciliary dyskinesia and RCT2100 for cystic fibrosis—are inhaled mRNA-based therapies using the SORT LNP platform. Both are designed for patient populations with no effective existing treatments. The company has raised significant funding ($260M Series B as of September 2023), has been recognized by Fierce Biotech’s “Fierce15” list and Nature’s “Seven Technologies to Watch,” but specific clinical results have not yet been published or detailed in public sources.

Therapeutic areas: GastroenterologyRheumatologyRare DiseasesNeurologyInfectious Diseases
Modalities: mRNA therapeuticsGene correction therapiesLipid nanoparticle (LNP) delivery systems (enabling technology)
Industry: Biotech

Drug pipeline

11 assets

RCT2100

10 more assets in the full pipeline.

Beyond the preview

Go deeper on ReCode Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReCode Therapeutics.